Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
21.05.24
09:36 Uhr
7,150 Euro
-0,030
-0,42 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
7,1507,17014:34
7,1507,17014:31

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.04.OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle250OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE's runway extension into 2026, past...
► Artikel lesen
16.04.OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective757OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 - OSE Immunotherapeutics SA...
► Artikel lesen
12.04.OSE Immunotherapeutics - Funding accelerates Tedopi clinical development216Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public funding from Bpifrance (a French public sector financing...
► Artikel lesen
10.04.OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi in Lung Cancer567OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Nantes, France - April 10, 2024 - 6:00 pm CET...
► Artikel lesen
02.04.OSE Immunotherapeutics - Pipeline momentum builds into FY24257OSE Immunotherapeutics' (OSE's) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal with AbbVie for preclinical asset OSE-230. The company...
► Artikel lesen
02.04.OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology61OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology Nantes, France - April 2, 2024 - 7:30 am CET - OSE Immunotherapeutics SA...
► Artikel lesen
27.03.OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update255Financial highlights €18.7 million available cash as of December 31st, 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February...
► Artikel lesen
19.03.OSE Immunotherapeutics - One step closer to key data readouts230OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical development of its novel anti-IL-7R antibody, OSE-127/Lusvertikimab...
► Artikel lesen
18.03.OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis197Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announced today the completion of patient enrollment in the Phase 2b clinical trial evaluating anti-IL-7...
► Artikel lesen
28.02.OSE Immunotherapeutics - Confidence boost with AbbVie partnership463OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for the treatment of chronic and severe inflammation. The...
► Artikel lesen
28.02.AbbVie and OSE Immunotherapeutics ink $713M deal7
28.02.AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody8
28.02.OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership709On February 28, 2024, at 6:00 p.m. CET 12:00 a.m. ET. Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE),will host a live webcast on February 28, 2024, at 6:00 p.m....
► Artikel lesen
28.02.AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation328Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront...
► Artikel lesen
28.02.AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics357BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie Inc. (ABBV) and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic...
► Artikel lesen
28.02.AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation154- Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation - OSE Immunotherapeutics to receive an upfront...
► Artikel lesen
27.02.OSE Immunotherapeutics - Encouraging OSE-279 clinical update193At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II dose escalation and expansion study for OSE-279, its anti-PD1...
► Artikel lesen
26.02.OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors328Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented an update on the positive results of OSE-279 in the Phase 1/2 clinical evaluation in advanced solid tumors...
► Artikel lesen
22.01.OSE Immunotherapeutics - Active year ahead for proprietary programmes349OSE has refreshed its outlook for 2024, including the commencement of the confirmatory Phase III trial for lead asset Tedopi (an off-the-shelf, neoepitope-based cancer vaccine) in second-line non-small...
► Artikel lesen
19.01.OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook274Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook. Nicolas Poirier, Chief Executive Officer...
► Artikel lesen
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1